“I remember the early days of Kit Check, where my co-founder Tim Kress-Spatz and I tirelessly educated hospitals about the remarkable efficiency and patient safety benefits of unit dose RFID. It was a challenging time, as we needed to convince adventurous pharmacists to take a leap of faith and apply RFID tags to thousands of doses. But they did, and with their visionary leadership, their peers soon followed suit. We worked closely with manufacturers to establish a rigorous certification process for RFID-tagged drugs, which helped build out the ecosystem for this technology in hospitals.

Fast forward to today, and hospitals that use KitCheck represent the majority of the market for RFID-tagged drugs. This is a testament to the power of perseverance and innovation. We are thrilled to see the broader industry recognizing the importance of investigating and publishing guidance on unit dose RFID serialization. The recent guidance from GS1 on the use of a partial cloud registry for RFID is a promising step in the right direction, and we continue to support multiple serialization schemes, including GS1 numbering systems. 

But it’s critical that we don’t want to stop there. At Bluesight, we are dedicated to going above and beyond to ensure that all supported items meet the rigorous quality and performance standards required by UnitVisID, regardless of the numbering scheme. By continually pushing the boundaries of what is possible, we can improve patient outcomes and elevate the entire industry.”

-Statement from Kevin MacDonald CEO & Co-Founder of Bluesight